BIRMINGHAM, Ala., Sept. 22 /PRNewswire/ -- Atherotech Diagnostics Lab will exhibit its VAP® Cholesterol Test in booth 121 at the Florida Osteopathic Medical Association (FOMA) Mid-Year Seminar held September 24-26 at the Grand Hyatt Tampa Bay in Tampa, Fla.
FOMA is the state association for osteopathic physicians in Florida and has been serving osteopathic physicians since 1904. The 2010 seminar will address advances in the science and art of osteopathic medicine. Cholesterol expert Paul Ziajka, M.D., who utilizes the VAP Test at the Florida Lipid Institute, will address "Inflammatory Markers and the Risk of Atherosclerosis" during the conference.
Atherotech's VAP Cholesterol Test is the only expanded lipid test that routinely reports directly measured LDL-C, which is included in the 22 separate components of cholesterol — all reported at no additional cost. Cholesterol subclasses include Lp(a), apoB, apoA1, and the apoB/apoA1 ratio, making the VAP Test the only lipid profile that routinely reports all three lipid parameters — LDL, non-HDL and apoB — considered necessary by the American Diabetes Association and American College of Cardiology. The comprehensive lipid profile also identifies markers of metabolic syndrome, often associated with early diabetes.
"The VAP Test goes far beyond the standard cholesterol test, providing a valuable research tool for cardiovascular science and detailed information for refining the clinical assessment of cardiovascular risk," said Atherotech Medical Advisory Board Member Gary H. Gibbons, M.D., a nationally recognized clinician-scientist and Director of the Cardiovascular Research Institute in Atlanta. "Because of its ability to report on dozens of cholesterol subclasses, the VAP Test holds great promise for playing a key role in advancing the understanding of heart disease risk and addressing disparities in cardiovascular health."
Atherotech provides physicians with a